Department of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea.
World Neurosurg. 2013 Dec;80(6):e261-6. doi: 10.1016/j.wneu.2012.09.013. Epub 2012 Sep 22.
The purpose of this study was to evaluate the efficacy and safety of gamma knife radiosurgery (GKRS) for the treatment of symptomatic brainstem intra-axial cavernous malformations (CMs) associated with high surgical morbidity.
Twenty-one patients with symptomatic brainstem intra-axial CMs were treated by GKRS between 2005 and 2010. One patient was lost to follow-up. The median age of the patients was 39.5 years (range, 24-69 years). All patients had experienced 1 or more symptomatic hemorrhages before GKRS (range, 1-3). The median marginal radiation dose was 13 Gy, and the median volume of the malformation was 0.56 mL. The median follow-up period after radiosurgery was 32 months (range, 12-82 months; mean, 38.9 months).
Before GKRS, 31 hemorrhages (1.55 per patient) were observed. The annual hemorrhage rate before GKRS was 39.5%, excluding the first hemorrhage. After GKRS, 1 hemorrhage (0.05 per patient) was identified. It occurred 6 months after radiosurgery. The patient showed complete recovery to a premorbid status with steroid medication. The annual hemorrhage rate after GKRS was 8.2% for the first 2 years. After the expected latency period, no hemorrhages were identified. One patient (5%) exhibited permanent paresthesia, which was a new neurologic symptom in absence of any hemorrhagic event, after the radiosurgery.
GKRS seems to be relatively effective and safe for reducing the rebleeding rate of brainstem intra-axial CMs that have high surgical risk. Careful selection of a low marginal dose and an optimal radiosurgical technique are helpful to achieve good outcomes.
本研究旨在评估伽玛刀放射外科(GKRS)治疗伴有高手术发病率的症状性脑干部位脑内轴内海绵状畸形(CM)的疗效和安全性。
2005 年至 2010 年间,21 例症状性脑干部位脑内轴内 CM 患者接受 GKRS 治疗。1 例患者失访。患者的中位年龄为 39.5 岁(范围,24-69 岁)。所有患者在 GKRS 治疗前均经历过 1 次或多次症状性出血(范围,1-3 次)。中位边缘照射剂量为 13 Gy,畸形体积中位数为 0.56 mL。GKRS 治疗后中位随访时间为 32 个月(范围,12-82 个月;平均 38.9 个月)。
GKRS 治疗前,共观察到 31 次出血(每位患者 1.55 次)。GKRS 治疗前每年的出血率为 39.5%,不包括首次出血。GKRS 治疗后,共发现 1 次出血(每位患者 0.05 次),发生在放射治疗后 6 个月。患者在接受类固醇药物治疗后完全恢复到发病前状态。GKRS 治疗后前 2 年,每年的出血率为 8.2%。在预期潜伏期后,未发现出血。GKRS 治疗后,1 例(5%)患者出现永久性感觉异常,这是一种在无任何出血事件的情况下出现的新的神经症状。
GKRS 似乎对降低高手术风险的脑干部位脑内轴内 CM 的再出血率具有较好的疗效和安全性。选择低边缘剂量和最佳放射外科技术有助于获得良好的结果。